[Skip navigation]FDA Logo links to FDA home page
Center for Drug Evaluation and Research, U.S. Food and Drug AdministrationU.S. Food and Drug AdministrationCenter for Drug Evaluation and Research
  HHS Logo links to Department of Health and Human Services website

FDA Home Page | CDER Home Page | CDER Site Info | Contact CDER | http://www.fda.gov/cder/whatsnew.htm

horizonal rule
CDER Home About CDER Drug Information Regulatory Guidance CDER Calendar Specific Audiences CDER Archives
Powered by Google

 Antidepressant Use in Children, Adolescents, and Adults

The Food and Drug Administration (FDA) requests a Warning Statement in the labeling for certain antidepressants to encourage close observation of adult and pediatric patients treated with these agents for worsening depression or the emergence of suicidality.  The drugs that are the focus of this new Warning Statement include: Prozac (fluoxetine); Zoloft (sertraline); Paxil (paroxetine); Luvox (fluvoxamine); Celexa (citalopram); Lexapro (escitalopram); Wellbutrin (bupropion); Effexor (venlafaxine); Serzone (nefazodone); and Remeron (mirtazapine). 

PDF files, marked with an icon PDF file: requires free Adobe Acrobat Reader, require the free Adobe Acrobat Reader.

Back to Top     Back to Drug Information

Date created: March 22, 2004, updated August 26, 2004

horizonal rule